glp 1 drugs news Compound versions of GLP-1 for weight loss halted by FDA Chart: 1 in 8 Americans

Wegovy contains the same main ingredient as Ozempic, semaglutide, and is FDA-approved for weight loss in people with obesity or who are overweight with at least one weight-related condition

So, typically the more effective the medication, the more likely the risk of adverse events

Front Cell Dev Biol (2020) 8:602574

In this context, the aim of the present document is to summarize, in the form of a narrative literature review, the currently available data on the main mechanisms of action of GIP/GLP-1 co-agonists and the clinical effects of tirzepatide evaluated in various clinical trials

If Saxenda or another branded GLP-1 agent is appropriate for your clinical picture, PlexusDx can support that decision with genetic context